BioCentury | Dec 2, 2020
Distillery Therapeutics

Neuraly’s GLP-1R agonist NLY01 for ocular hypertension

...II testing for Parkinson’s.Eli Lilly and Co. (NYSE:LLY) and Sumitomo Dainippon Pharma Co. Ltd. (Tokyo:4506) market Trulicity dulaglutide...
BioCentury | Sep 2, 2020
Management Tracks

Namouni to lead Blueprint R&D; plus Davar to head R&D at Acadia, Napolitano replaces Burow on Vir’s board, and more

...tenure. At Lilly, Wroblewski contributed to the commercial launch of biologics including Erbitux cetuximab, Taltz ixekizumab and Trulicity dulaglutide.The...
BioCentury | Feb 26, 2020
Product Development

Regulatory Roundup: FDA reviewing GSK, Takeda applications for earlier lines of cancer treatment; plus Novartis, Halozyme-Genentech, MacroGenics, CSL, Lilly

...of CSL Ltd. (ASX:CSL), is the first approved quadrivalent vaccine. The agency also approved Trulicity dulaglutide...
...Type II diabetes who have established CV disease or multiple risk factors. The company said Trulicity...
...ofatumumab (OMB157, humax-cd20, 2F2) Herceptin, trastuzumab (RG597) Perjeta, pertuzumab (R1273, RG1273, 2C4, Omnitarg, rhuMAb-2C4) margetuximab (MGAH22) GLP-1Fc, Trulicity, dulaglutide (LY2189265) GlaxoSmithKline...
BioCentury | Oct 24, 2019
Financial News

Lilly shares slide amid Trulicity, Taltz pricing concerns

...sales of Type II diabetes drug Trulicity dulaglutide and psoriasis drug Taltz ixekizumab. Sales of Trulicity...
...changes in segment mix and increased gap-funding requirements under Medicare Part D. U.S. revenue for Trulicity...
...substantially going forward,” said Lilly SVP and CFO Joshua Smiley on the call. “We think Trulicity's...
BioCentury | Sep 20, 2019
Company News

Xospata poised for EU approval under accelerated assessment

...nasal polyposis; Lucentis ranibizumab from Novartis AG (NYSE:NVS; SIX:NOVN) for proliferative diabetic retinopathy; and Trulicity dulaglutide...
...Brand), RG3645 (Compound #), rhuFab V2 (Former compound #), ranibizumab (Generic), Lucentis (Informal) GLP-1Fc, Trulicity, dulaglutide (LY2189265) NutreStore...
BioCentury | Sep 20, 2019
Company News

Approval of Novo’s Rybelsus gives diabetes patients first oral option in GLP-1R class

...subcutaneous formulation of semaglutide, Ozempic, has a WAC of $772.43 per month; GLP-1R agonist Trulicity dulaglutide...
...Eaton, Staff Writer oral semaglutide (NN9924, OG217SC) Ozempic (Brand), NN9535 (Compound #), subcutaneous semaglutide (Informal) GLP-1Fc, Trulicity, dulaglutide (LY2189265) Victoza...
BioCentury | Apr 30, 2019
Company News

Lilly reports lower sales in drugs with higher rebates

...Type II diabetes drug Trulicity dulaglutide and psoriasis drug Taltz ixekizumab. Lilly said increase in Trulicity...
...in the first quarter was partially offset by changes in estimates to rebates and discounts. Trulicity...
...the Street's $1.31 estimate. Consensus figures provided by FactSet. Elizabeth S. Eaton, Staff Writer GLP-1Fc, Trulicity, dulaglutide (LY2189265) Taltz...
BioCentury | Feb 7, 2019
Politics & Policy

J&J to include drug pricing in TV ads

...and Co. (NYSE:LLY) Chairman and CEO Dave Ricks, the pharma now includes in its Trulicity dulaglutide...
BioCentury | Jan 3, 2019
Distillery Therapeutics

Endocrine/metabolic

...mAb. And in the same model, the mAb plus the GLP-1R agonists Victoza liraglutide, Trulicity dulaglutide...
...agent alone. In an NHP model of spontaneous obesity, a human anti-GIP receptor mAb plus Trulicity...
...J. Lloyd, Amgen Inc., Thousand Oaks, Calif. email: dlloyd@amgen.com Claire Quang Byetta, exenatide (AC2993, Exendin-4) GLP-1Fc, Trulicity, dulaglutide (LY2189265) Victoza...
BioCentury | Dec 8, 2018
Strategy

Novo gets serious about AI-guided drug design

...HbA1c by 1.8% and mean weight by 6.5 kg, compared with 1.5 mg once-weekly Trulicity dulaglutide...
Items per page:
1 - 10 of 64